Trial Sample size & population Intervention Formulation and Route of Administration Trial Sponsor Trial recruitment status
NCT04592835 Phase 1 to assess safety, tolerability, PK
24 healthy volunteers
DWRX2003 (niclosamide i.m.) vs placebo single ascending dose study
i.m.
Daewoong Pharmaceutical Co
Not yet recruiting
NCT04524052 Phase 1 to assess safety, tolerability, PK/PD
32 healthy volunteers
DWRX2003 (niclosamide i.m. depot) vs placebo
i.m.
Daewoong Pharmaceutical Co
Not yet recruiting
NCT04749173 Phase 1 safety, tolerability and PK
24 healthy volunteers
DWRX2003 (niclosamide i.m.) vs placebo
i.m.
Daewoong Pharmaceutical Co
Recruiting
NCT04541485 Phase 1 to assess safety, tolerability and PD 40 COVID-19 patients (low-moderate risk) DWRX2003 (niclosamide i.m. depot) vs placebo i.m. Daewoong Pharmaceutical Co Not yet recruiting
NCT04644705 Phase 1 to assess safety and PK
28 healthy volunteers
Niclosamide and camostat vs placebo
p.o, tablet and novel galenic preparation
Charité Research Organisation GmbH
Recruiting
EUCTR2020-002233-15-DE Phase 2
40 participants with mild-moderate COVID-19
Niclosamide and camostat tablet vs placebo
p.o, tablet
Charité Research Organisation GmbH
Suspended (to pandemic situation)
NCT04576312 Phase 1
64 healthy volunteers
UNI911 (niclosamide inhalation + nasal spray) vs placebo
Solution for inhalation and intranasal application
UNION therapeutics
Completed, results published Backer et al. (2021)
NCT04932915 Phase 2 study to assess safety and efficacy 330 asymptomatic or mild COVID-19 participants UNI91103 (niclosamide nasal spray) vs placebo Solution for intranasal application UNION therapeutics Not yet recruiting
NCT04870333 Phase 2/3 Chemoprophylaxis trial in vulnerable patients
1500 participants from vulnerable patient populations
UNI91103 (niclosamide nasal spray) vs placebo
Solution for intranasal application
Cambridge University Hospitals NHS Foundation Trust
Recruiting
NCT04436458 Phase 2
100 participants with moderate COVID-19 with gastrointestinal signs symptoms
Niclosamide + SoC vs placebo
p.o, tablet
First Wave Bio
Not yet recruiting
NCT04542434 Phase 2
148 participants with moderate COVID-19 with gastrointestinal signs symptoms
Niclosamide vs placebo
p.o, tablet
First Wave Bio
Not yet recruiting
NCT04603924 Phase 2/3
436 participants with moderate-severe COVID-19
ANA001 (niclosamide capsules) vs placebo
p.o, capsules
NeuroBo Pharmaceuticals
Recruiting
NCT04558021 Phase 3
200 patients with moderate COVID-19
Novel niclosamide suspension formulation as add-on to SoC vs placebo
p.o, suspension
Imuneks Farma ilac San
Recruiting
NCT04753619 Phase 2 open label randomized controlled trial 150 patients with COVID-19 ranging from mild-severe Niclosamide add on to standard of care p.o, tablet University of Baghdad Completed, results published Abdulamir et al. (2021)
NCT04399356 Phase 2
73 participants with mild-moderate COVID-19
Niclosamide + SoC vs placebo
p.o, tablet
Tufts Medical Center
Active, not recruiting
NCT04858425 Phase 2
148 participants with COVID-19 gastrointestinal infection
Niclosamide vs placebo
p.o, tablet
AzurRx BioPharma
Recruiting
CTRI/2020/04/024949 phase 2 48 participants with very mild COVID-19 Niclosamide add on to standard of care p.o, tablet Lady Hardinge Medical College Recruiting
TACTIC-E/ NCT04393246 Phase 2/3
~469 participants with moderate-severe covid (pre-ICU)
EDP1815, dapagliflozin, ambrisentan, niclosamide, SoC
Solution for nebulization and intranasal application
Cambridge University Hospitals NHS Foundation Trust
Recruiting